GILEAD SCIENCES, INC. (GILD) FY2026 Q1 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-01-01 to 2026-03-31

Swipe to see the full flow
GILEAD SCIENCES, INC. cash flow reconciliation, Jan 1, 2026 through Mar 31, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Calculated remaining financing cash flows are purple; remaining operating and investing bundles are gray. Their underlying inflows and outflows are not separately identified. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $2,021,000,000.00Amortization expense → Operating adjustments reconciliation: $596,000,000.00Stock-based compensation expense → Operating adjustments reconciliation: $218,000,000.00Other, net → Operating adjustments reconciliation: $183,000,000.00Deferred income taxes → Operating adjustments reconciliation: $179,000,000.00Accounts receivable, net → Operating adjustments reconciliation: $134,000,000.00Acquired in-process research and development expenses → Operating adjustments reconciliation: $107,000,000.00Depreciation expense → Operating adjustments reconciliation: $93,000,000.00Prepaid expenses and other → Operating adjustments reconciliation: $5,000,000.00Operating adjustments reconciliation → Net cash from operating activities: $523,000,000.00Operating adjustments reconciliation → Accrued and other liabilities: $702,000,000.00Operating adjustments reconciliation → Net (gain) loss from equity securities: $142,000,000.00Operating adjustments reconciliation → Accounts payable: $67,000,000.00Operating adjustments reconciliation → Inventories: $52,000,000.00Operating adjustments reconciliation → Income tax assets and liabilities, net: $29,000,000.00Proceeds from sales of marketable debt securities → investing reconciliation: $2,520,000,000.00Proceeds from maturities of marketable debt securities → investing reconciliation: $36,000,000.00Remaining investing cash flows, net (calculated) → investing reconciliation: $1,000,000.00investing reconciliation → Net cash from investing activities: $1,770,000,000.00investing reconciliation → Purchases of marketable debt securities: $525,000,000.00investing reconciliation → Purchases of property, plant and equipment: $117,000,000.00investing reconciliation → Acquisitions, including in-process research and development, net of cash acquired: $109,000,000.00investing reconciliation → Purchases of equity securities: $19,000,000.00investing reconciliation → Other investing activities, net: $17,000,000.00Net cash used in financing activities → financing reconciliation: $4,239,000,000.00Proceeds from issuances of common stock → financing reconciliation: $166,000,000.00financing reconciliation → Repayments of debt and other obligations: $2,766,000,000.00financing reconciliation → Payments of dividends: $1,040,000,000.00financing reconciliation → Repurchases of common stock under repurchase programs: $419,000,000.00financing reconciliation → Other financing activities, net: $179,000,000.00financing reconciliation → Remaining financing cash flows, net (calculated): $1,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $7,564,000,000.00Net cash from operating activities → Cash sources and uses: $2,544,000,000.00Net cash from investing activities → Cash sources and uses: $1,770,000,000.00Cash sources and uses → Exchange-rate effect: $11,000,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $7,628,000,000.00Cash sources and uses → Net cash used in financing activities: $4,239,000,000.00Income tax assets and liabilities, net: -$29,000,000.00Income tax balances−$29.00 MNet income: $2,021,000,000.00Net income+$2.02 BAcquired in-process research and development expenses: $107,000,000.00Acquired IPR&D written off+$107.00 MAccrued and other liabilities: -$702,000,000.00Accrued liabilities−$702.00 MAmortization expense: $596,000,000.00Amortization expense+$596.00 MOther, net: $183,000,000.00Other non-cash items+$183.00 MStock-based compensation expense: $218,000,000.00Stock-based compensation+$218.00 MNet (gain) loss from equity securities: -$142,000,000.00Equity securities, net−$142.00 MAccounts payable: -$67,000,000.00Accounts payable−$67.00 MDeferred income taxes: $179,000,000.00Deferred income taxes+$179.00 MPrepaid expenses and other: $5,000,000.00Prepaid & other assets+$5.00 MInventories: -$52,000,000.00Inventories−$52.00 MDepreciation expense: $93,000,000.00Depreciation expense+$93.00 MAccounts receivable, net: $134,000,000.00Accounts receivable+$134.00 MNet cash from operating activities: $2,544,000,000.00Operating cash+$2.54 BOperating adjustments reconciliation: $1,515,000,000.00Proceeds from issuances of common stock: $166,000,000.00Common stock issued+$166.00 MPayments of dividends: -$1,040,000,000.00Dividends paid−$1.04 BRepurchases of common stock under repurchase programs: -$419,000,000.00Common stock repurchases−$419.00 MOther financing activities, net: -$179,000,000.00Other financing, net−$179.00 MRepayments of debt and other obligations: -$2,766,000,000.00Debt repaid−$2.77 BRemaining financing cash flows, net (calculated): -$1,000,000.00Remaining financing (calculated)−$1.00 MNet cash used in financing activities: -$4,239,000,000.00. Cash required to fund net payments.Financing cash−$4.24 Bfinancing reconciliation: $4,405,000,000.00Purchases of equity securities: -$19,000,000.00Other investment purchases−$19.00 MPurchases of marketable debt securities: -$525,000,000.00AFS securities purchases−$525.00 MPurchases of property, plant and equipment: -$117,000,000.00PP&E purchases−$117.00 MAcquisitions, including in-process research and development, net of cash acquired: -$109,000,000.00Acquisitions, net of cash−$109.00 MOther investing activities, net: -$17,000,000.00Other investing, net−$17.00 MProceeds from sales of marketable debt securities: $2,520,000,000.00AFS securities sales+$2.52 BProceeds from maturities of marketable debt securities: $36,000,000.00AFS securities maturities+$36.00 MRemaining investing cash flows, net (calculated): $1,000,000.00Remaining investing (calculated)+$1.00 MNet cash from investing activities: $1,770,000,000.00Investing cash+$1.77 Binvesting reconciliation: $2,557,000,000.00Cash sources and uses: $11,878,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $7,564,000,000.00Beginning cash$7.56 BEnding cash: Cash, cash equivalents, and restricted cash: $7,628,000,000.00Ending cash$7.63 BExchange-rate effect: -$11,000,000.00FX effect−$11.00 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$2.43 BOperating cash − cash spent on PP&ECash flow / Net income1.26×Operating cash flow ÷ net incomeNet cash change+$64.00 MEnding cash − beginning cash
Chart details

GILEAD SCIENCES, INC. cash flow reconciliation, Jan 1, 2026 through Mar 31, 2026

Cash flows for Jan 1, 2026 through Mar 31, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Mar 31, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
7,564,000,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
2,544,000,000 US dollars. Net cash provided.
Net income
2,021,000,000 US dollars
Income tax assets and liabilities, net
negative 29,000,000 US dollars
Acquired in-process research and development expenses
107,000,000 US dollars
Accrued and other liabilities
negative 702,000,000 US dollars
Amortization expense
596,000,000 US dollars
Other, net
183,000,000 US dollars
Stock-based compensation expense
218,000,000 US dollars
Net (gain) loss from equity securities
negative 142,000,000 US dollars
Accounts payable
negative 67,000,000 US dollars
Deferred income taxes
179,000,000 US dollars
Prepaid expenses and other
5,000,000 US dollars
Inventories
negative 52,000,000 US dollars
Depreciation expense
93,000,000 US dollars
Accounts receivable, net
134,000,000 US dollars
Investing activities
1,770,000,000 US dollars. Net cash provided. The remaining amount is calculated by subtracting the other displayed items from the investing total. The filing's tagged investing lines do not add up to the investing total; this is the difference. It may combine inflows and outflows.
Purchases of equity securities
negative 19,000,000 US dollars
Purchases of marketable debt securities
negative 525,000,000 US dollars
Purchases of property, plant and equipment
negative 117,000,000 US dollars
Acquisitions, including in-process research and development, net of cash acquired
negative 109,000,000 US dollars
Other investing activities, net
negative 17,000,000 US dollars
Proceeds from sales of marketable debt securities
2,520,000,000 US dollars
Proceeds from maturities of marketable debt securities
36,000,000 US dollars
Remaining investing cash flows, net (calculated)
1,000,000 US dollars
Financing activities
negative 4,239,000,000 US dollars. Net cash used. The remaining amount is calculated by subtracting the other displayed items from the financing total. The filing's tagged financing lines do not add up to the financing total; this is the difference. It may combine inflows and outflows.
Proceeds from issuances of common stock
166,000,000 US dollars
Payments of dividends
negative 1,040,000,000 US dollars
Repurchases of common stock under repurchase programs
negative 419,000,000 US dollars
Other financing activities, net
negative 179,000,000 US dollars
Repayments of debt and other obligations
negative 2,766,000,000 US dollars
Remaining financing cash flows, net (calculated)
negative 1,000,000 US dollars
Operating adjustment reconciliation
1,515,000,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing displayed reconciliation
4,405,000,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
investing displayed reconciliation
2,557,000,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
Exchange-rate effect
negative 11,000,000 US dollars
Ending cash on Mar 31, 2026
7,628,000,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
11,878,000,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
64,000,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
1.26×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
2,544,000,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
117,000,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
2,427,000,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $523.00M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • The filer's reported cash figures differ by $1.00 M: its operating, investing and financing totals, its reported net change in cash and the move from its beginning to its ending cash do not all agree. The chart shows the difference as its own calculated flow; no reported amount has been adjusted.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 2,544,000,000 US dollars minus 117,000,000 US dollars equals 2,427,000,000 US dollars.
  • The filer's reported cash figures differ by $1.00 M: its operating, investing and financing totals, its reported net change in cash and the move from its beginning to its ending cash do not all agree. The chart shows the difference as its own calculated flow; no reported amount has been adjusted.
GILEAD SCIENCES, INC. (GILD) FY2026 Q1 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!